One Difference Between Amylyx’s ALS Drug And Aduhelm: A Biomarker Endpoint

US FDA’s Billy Dunn says that if the drug had shown a positive effect on plasma neurofilament heavy chain, it ‘would have provided important contextual and supportive information of an ostensibly beneficial effect on the clinical measure.’